May 20, 2022
A key health ministry panel will discuss on June 1 whether to grant an orphan status to Pfizer’s fidanacogene elaparvovec, a gene therapy for hemophilia B. The product contains a bio-engineered adeno-associated virus capsid and a high-activity human coagulation factor...read more